Literature DB >> 110993

Hypolipidemic effects in monkeys of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase.

M Kuroda, Y Tsujita, K Tanzawa, A Endo.   

Abstract

The fungal metabolite ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl CoA reductase, has been shown to be significantly effective in lowering serum cholesterol levels in cynomolgus monkeys at doses of 20-50 mg/kg per day. Levels of serum phospholipids and triglycerides were, however, not significantly changed by the administration of the drug. Of the serum lipoprotein fractions, a beta-lipoprotein corresponding to low density lipoprotein was preferentially reduced by the drug treatment. Fecal excretion of neutral sterols was unaffected but that of bile acids and slightly elevated by the administration of ML-236B.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 110993     DOI: 10.1007/bf02533537

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  10 in total

1.  QUANTITATIVE ISOLATION AND GAS--LIQUID CHROMATOGRAPHIC ANALYSIS OF TOTAL FECAL BILE ACIDS.

Authors:  S M GRUNDY; E H AHRENS; T A MIETTINEN
Journal:  J Lipid Res       Date:  1965-07       Impact factor: 5.922

2.  ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium.

Authors:  A Endo; M Kuroda; Y Tsujita
Journal:  J Antibiot (Tokyo)       Date:  1976-12       Impact factor: 2.649

3.  Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity.

Authors:  A Endo; M Kuroda; K Tanzawa
Journal:  FEBS Lett       Date:  1976-12-31       Impact factor: 4.124

4.  Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.

Authors:  A Endo; Y Tsujita; M Kuroda; K Tanzawa
Journal:  Eur J Biochem       Date:  1977-07-01

5.  Effects of colestipol hydrochloride (U-26,597A) on serum and fecal lipids in dogs.

Authors:  T M Parkinson; J C Schneider; W A Phillips
Journal:  Atherosclerosis       Date:  1973 Mar-Apr       Impact factor: 5.162

6.  Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase.

Authors:  M S Brown; J R Faust; J L Goldstein; I Kaneko; A Endo
Journal:  J Biol Chem       Date:  1978-02-25       Impact factor: 5.157

7.  Disc electrophoresis of rat plasma lipoproteins.

Authors:  K A Narayan; H L Creinin; F A Kummerow
Journal:  J Lipid Res       Date:  1966-01       Impact factor: 5.922

8.  Inhibitory effects on lipid metabolism in cultured cells of ML-236B, a potent inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase.

Authors:  I Kaneko; Y Hazama-Shimada; A Endo
Journal:  Eur J Biochem       Date:  1978-06-15

9.  Hypolipidemic effects in dogs of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase.

Authors:  Y Tsujita; M Kuroda; K Tanzawa; N Kitano; A Endo
Journal:  Atherosclerosis       Date:  1979-03       Impact factor: 5.162

10.  An overview of the biochemical pharmacology of probucol.

Authors:  J W Barnhart; D J Rytter; J A Molello
Journal:  Lipids       Date:  1977-01       Impact factor: 1.880

  10 in total
  11 in total

Review 1.  Lipid parameters for measuring risk of cardiovascular disease.

Authors:  Benoit J Arsenault; S Matthijs Boekholdt; John J P Kastelein
Journal:  Nat Rev Cardiol       Date:  2011-02-01       Impact factor: 32.419

2.  Treatment of hypercholesterolemia with the HMG CoA reductase inhibitor, simvastatin.

Authors:  G M Berger; A D Marais; H C Seftel; S G Baker; D Mendelsohn; N H Welsh; B I Joffe
Journal:  Cardiovasc Drugs Ther       Date:  1989-04       Impact factor: 3.727

3.  Feedback regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in livers of mice treated with mevinolin, a competitive inhibitor of the reductase.

Authors:  T Kita; M S Brown; J L Goldstein
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

4.  Effects of pravastatin and ursodeoxycholic acid on cholesterol and bile acid metabolism in patients with cholesterol gallstones.

Authors:  S Okamoto; K Nakano; K Kosahara; M Kishinaka; H Oda; H Ichimiya; K Chijiiwa; S Kuroki
Journal:  J Gastroenterol       Date:  1994-02       Impact factor: 7.527

Review 5.  Isoprenoids: remarkable diversity of form and function.

Authors:  Sarah A Holstein; Raymond J Hohl
Journal:  Lipids       Date:  2004-04       Impact factor: 1.880

6.  Brain and optic system pathology in hypocholesterolemic dogs treated with a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase.

Authors:  P H Berry; J S MacDonald; A W Alberts; S Molon-Noblot; J S Chen; C Y Lo; M D Greenspan; H Allen; G Durand-Cavagna; R Jensen
Journal:  Am J Pathol       Date:  1988-09       Impact factor: 4.307

Review 7.  Chemistry, biochemistry, and pharmacology of HMG-CoA reductase inhibitors.

Authors:  A Endo
Journal:  Klin Wochenschr       Date:  1988-05-16

8.  Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent.

Authors:  A W Alberts; J Chen; G Kuron; V Hunt; J Huff; C Hoffman; J Rothrock; M Lopez; H Joshua; E Harris; A Patchett; R Monaghan; S Currie; E Stapley; G Albers-Schonberg; O Hensens; J Hirshfield; K Hoogsteen; J Liesch; J Springer
Journal:  Proc Natl Acad Sci U S A       Date:  1980-07       Impact factor: 11.205

9.  Effects of ML-236b (compactin) on sterol synthesis and low density lipoprotein receptor activities in fibroblasts of patients with homozygous familial hypercholesterolemia.

Authors:  T Haba; H Mabuchi; A Yoshimura; A Watanabe; T Wakasugi; R Tatami; K Ueda; R Ueda; T Kametani; J Koizumi; S Miyamoto; R Takeda; H Takeshita
Journal:  J Clin Invest       Date:  1981-05       Impact factor: 14.808

Review 10.  A historical perspective on the discovery of statins.

Authors:  Akira Endo
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2010       Impact factor: 3.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.